Literature DB >> 1986828

Screening for hypercholesterolemia among Canadians: how much will it cost?

S A Grover1, L Coupal, R Fahkry, S Suissa.   

Abstract

OBJECTIVE: To determine the cost of screening all Canadians aged 30 years or more without coronary heart disease (CHD) for hypercholesterolemia. DATA SOURCES: The expected results of initial screening of the serum cholesterol level were estimated on the basis of 1986 Canadian census data and the 1978 Canada Health Survey. The results of repeat testing were estimated on the basis of data from the Lipid Research Clinics Prevalence Study. Lipid profile results were extrapolated from tests at the Montreal General Hospital's clinical chemistry laboratory. Laboratory costs and primary care practitioner costs were provided by the Canadian Society of Clinical Chemists and provincial fee schedules respectively. MAIN
RESULTS: Among 12,479,356 Canadians free of CHD 48.7% would be identified as being at high risk, 4.8% would be identified as being at moderate risk, and 46.6% would be reassured that their lipid risk for CHD was low. The total cost of implementing the program in the first year would be $432 million to $561 million ($325 million for laboratory tests and $107 million to $236 million for visits to primary care practitioners).
CONCLUSION: The substantial cost of implementing a nationwide screening program must be weighed against the expected benefits to ensure that the final result is both practical and economically feasible.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1986828      PMCID: PMC1453000     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  17 in total

1.  A physician's guide to lipoprotein metabolism.

Authors:  J A Little
Journal:  CMAJ       Date:  1989-09-15       Impact factor: 8.262

2.  The public health approach: the Nova Scotia experience. Canadian Atherosclerosis Society.

Authors:  D R MacLean
Journal:  CMAJ       Date:  1989-10-15       Impact factor: 8.262

3.  Cost-effectiveness of interventions to prevent or treat coronary heart disease.

Authors:  M C Weinstein; W B Stason
Journal:  Annu Rev Public Health       Date:  1985       Impact factor: 21.981

4.  Cost-effectiveness of antihyperlipemic therapy in the prevention of coronary heart disease. The case of cholestyramine.

Authors:  G Oster; A M Epstein
Journal:  JAMA       Date:  1987-11-06       Impact factor: 56.272

5.  Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease.

Authors:  M H Frick; O Elo; K Haapa; O P Heinonen; P Heinsalmi; P Helo; J K Huttunen; P Kaitaniemi; P Koskinen; V Manninen
Journal:  N Engl J Med       Date:  1987-11-12       Impact factor: 91.245

6.  Comparisons of referral criteria for public screening of blood cholesterol levels.

Authors:  R G Wones; K M Kerman; D C Hissa; N Meloy; E A Stein
Journal:  Public Health Rep       Date:  1989 Sep-Oct       Impact factor: 2.792

7.  Cholesterol and mortality. 30 years of follow-up from the Framingham study.

Authors:  K M Anderson; W P Castelli; D Levy
Journal:  JAMA       Date:  1987-04-24       Impact factor: 56.272

8.  Retest reliability of plasma cholesterol and triglyceride. The Lipid Research Clinics Prevalence Study.

Authors:  D R Jacobs; E Barrett-Connor
Journal:  Am J Epidemiol       Date:  1982-12       Impact factor: 4.897

9.  Cholesterol reduction and life expectancy. A model incorporating multiple risk factors.

Authors:  W C Taylor; T M Pass; D S Shepard; A L Komaroff
Journal:  Ann Intern Med       Date:  1987-04       Impact factor: 25.391

10.  Cutting into cholesterol. Cost-effective alternatives for treating hypercholesterolemia.

Authors:  B P Kinosian; J M Eisenberg
Journal:  JAMA       Date:  1988-04-15       Impact factor: 56.272

View more
  8 in total

Review 1.  Resource utilisation in the management of dyslipidaemia.

Authors:  T D Szucs
Journal:  Pharmacoeconomics       Date:  1998       Impact factor: 4.981

Review 2.  Cost-effectiveness of drug therapy for hypercholesterolaemia: a review of the literature.

Authors:  D Thompson; G Oster
Journal:  Pharmacoeconomics       Date:  1992-07       Impact factor: 4.981

Review 3.  Simvastatin: a pharmacoeconomic evaluation of its cost-effectiveness in hypercholesterolaemia and prevention of coronary heart disease.

Authors:  P Chrisp; N J Lewis; R J Milne
Journal:  Pharmacoeconomics       Date:  1992-02       Impact factor: 4.981

4.  Screening in the office for elevated cholesterol levels: still a dilemma.

Authors:  P P Morgan; E A Lindsay
Journal:  CMAJ       Date:  1994-07-01       Impact factor: 8.262

Review 5.  Economic evaluation of cholesterol-related interventions in general practice. An appraisal of the evidence.

Authors:  T van der Weijden; J A Knottnerus; A J Ament; H E Stoffers; R P Grol
Journal:  J Epidemiol Community Health       Date:  1998-09       Impact factor: 3.710

Review 6.  Simvastatin. A reappraisal of its cost effectiveness in dyslipidaemia and coronary heart disease.

Authors:  K L Goa; L B Barradell; D McTavish
Journal:  Pharmacoeconomics       Date:  1997-01       Impact factor: 4.981

7.  Do doctors accurately assess coronary risk in their patients? Preliminary results of the coronary health assessment study.

Authors:  S A Grover; I Lowensteyn; K L Esrey; Y Steinert; L Joseph; M Abrahamowicz
Journal:  BMJ       Date:  1995-04-15

8.  Modifying serum lipids to prevent coronary heart disease: do we have a consensus?

Authors:  S A Grover
Journal:  Cardiovasc Drugs Ther       Date:  1993-11       Impact factor: 3.727

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.